GSK Plc ADR(GSK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 9:23 AM ET (Korea 10/27 22:23)
Full metrics table
| Index | - | P/E | 16.1 | EPS (ttm) | 3.17 | Insider Own | 0.01% | Shs Outstand | 2.02B | Perf Week | 3.32% |
| Market Cap | 102.38B | Forward P/E | 10.13 | EPS next Y | 5.59% | Insider Trans | - | Shs Float | 2.00B | Perf Month | 3.78% |
| Enterprise Value | 121.84B | PEG | 2.41 | EPS next Q | 1.33 | Inst Own | 17.41% | Short Float | 0.74% | Perf Quarter | -4.86% |
| Income | 6.48B | P/S | 2.3 | EPS this Y | 1.59% | Inst Trans | -2.07% | Short Ratio | 3.56 | Perf Half Y | -5.75% |
| Sales | 44.55B | P/B | 4.41 | EPS next 5Y | 4.21% | ROA | 7.95% | Short Interest | 14.80M | Perf YTD | 4.2% |
| Book/sh | 11.58 | P/C | 24.83 | EPS past 3/5Y | -25.93% 0.08% | ROE | 29.69% | 52W High | -17.17% ($61.69) | Perf Year | 18.18% |
| Cash/sh | 2.06 | P/FCF | 11.74 | Sales past 3/5Y | 6.03% -0.31% | ROIC | 15.47% | 52W Low | 19.27% ($42.85) | Perf 3Y | 43.22% |
| Dividend Est. | $1.85 (3.61%) | EV/EBITDA | 8.63 | EPS Y/Y TTM | 48.32% | Gross Margin | 73.29% | Volatility(W/M) | 1.75% 1.7% | Perf 5Y | 24.93% |
| Dividend TTM | 1.82 | EV/Sales | 2.73 | Sales Y/Y TTM | 8.82% | Oper. Margin | 25% | ATR (14) | 1 | Perf 10Y | 24.43% |
| Dividend Ex-Date | 2026/8/14 | Quick Ratio | 0.52 | EPS Q/Q | -69.33% | Profit Margin | 14.56% | RSI (14) | 61.33 | Recom | 2.22 |
| Dividend Gr. 3/5Y | 8.77% -7.68% | Current Ratio | 0.82 | Sales Q/Q | 5.87% | SMA20 | 5.61% ($48.39) | Beta | 0.3 | Target Price | $56.34 |
| Payout | 46.93% | Debt/Eq | 1.03 | Earnings | 2026/10/28 | SMA50 | 3.02% ($49.6) | Rel Volume | 0.87 | Prev Close | $50.75 |
| Employees | 66841 | LT Debt/Eq | 0.79 | EPS/Sales Surpr. | 8.28% 1.42% | SMA200 | -2.41% ($52.36) | Avg Volume(3M) | 4.16M | Price | $51.1 |
| IPO | 1980/3/28 | Option/Short | Yes/Yes | Trades | 22803 | Volume | 3,609,438 | Change | 0.69% |
💉 A global pharmaceutical company that provides vaccines and specialty medicines (in HIV, respiratory, immunology, oncology, and general pharmaceuticals). It was formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000 and is headquartered in the UK. It has established itself as a leading player in the global vaccines market.
Over the past 1 year, roughly in the middle
17% below its 1-year high.
Traded about as much as usual. That is 87% of its average volume.
Next earnings report: October 28
1 days to go.
GSK makes money but has a weak balance sheet
Of every $100 in sales, $25.00 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +1.6% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $1,013. Peers typically go for $1,518.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 5 years ago, your return today would be +24.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 3.61% annually in dividends.
Tap to view numbers
Ownership is about average
Institutions hold 17.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
GSKH GSK plc ADRhedged 0.97% 
PPH VanEck Pharmaceutical ETF 0.04% 
KEAT Keating Active ETF 0.04% 
DIVY Sound Equity Dividend Income ETF 0.04% 
IDVZ Polen International Dividend Income Fund 0.03% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
GSKH GSK plc ADRhedged - It ranks #12 of 21 in the industry
Based on market cap of $102B.
PFE#9 Pfizer Inc $170B PER 39.5 
NVO#10 Novo Nordisk ADR $131B PER 9.6 
BMY#11 Bristol-Myers Squibb Co $126B PER 13.6 
GSK#12 GSK Plc ADR $102B PER 16.1 
SNY#13 Sanofi ADR $100B PER 21.5 
FAQ
What kind of company is GSK?
GSK belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of GSK?
The market cap of GSK is approximately $102.4B, ranking 160 within its sector.
Does GSK pay dividends?
GSK has a dividend yield of approximately 3.61%, with an annual dividend of $1.85.
What is the P/E ratio of GSK?
GSK has a P/E ratio of approximately 16.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for GSK?
GSK has recorded a 52-week high of $61.69 and a low of $42.85.
